Healthcare tech firm Indegene has announced the acquisition of BioPharm, a Pennsylvania-based specialised marketing services agency and part of Omnicom Health Group, for $106 million. BioPharm delivers marketing and communications solutions to life sciences clients across North America.

Acquisition to boost Indegene’s AI led pharma marketing portfolio

The deal, executed through Indegene’s subsidiary ILSL Inc., aims to strengthen Indegene’s commercialisation portfolio and expand its AI-powered marketing and AdTech capabilities for global pharmaceutical companies. BioPharm, which employs more than 90 people in the US, reported revenues of $38.13 million in 2024 and specialises in data-driven healthcare provider marketing solutions.

BioPharma brings top global biopharma clients to Inde

See Full Page